RecruitingNot ApplicableNCT06720571

Effects of Transcutaneous Vagus Nerve Stimulation on Emotion Regulation and Executive Functioning in Prader-Willi Syndrome

Auricular Vagal Neuromodulation Therapy (aVNT) for Enhancing Emotion Regulation, Executive Functions, Hyperphagia, and Quality of Life in Prader-Willi Syndrome: A Multicenter Randomized Controlled Trial


Sponsor

University of Bordeaux

Enrollment

24 participants

Start Date

Nov 22, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The STIM-PRADER study aims to assess the effectiveness of auricular vagal neuromodulation therapy (aVNT) on emotional, behavioral, and cognitive domains impaired in Prader-Willi Syndrome (PWS). Currently, no treatment exists that addresses the multiple alterations associated with this rare neurodevelopmental disorder that significantly impact patients and their families. We will investigate the effects of daily, four-hour aVNT stimulation over a nine-month period on (a) emotion regulation, including assessing the persistence of effects following stimulation; (b) executive functions, including inhibition, flexibility, planning, and updating information in memory; (c) hyperphagia; (d) depression; (e) quality of life; (e) and the threshold at which effects on these dimensions can be observed. We will conduct a longitudinal multicenter parallel randomized controlled single-blind exploratory trial. Twenty-four adults with PWS and 24 caregivers will be randomly assigned to receive either active or sham stimulation under identical conditions (four hours per day, seven days per week over nine months). The primary outcome, focusing on emotional control, will be assessed every two weeks for both participants and caregivers. Secondary outcomes (executive functions, hyperphagia, depression, and quality of life) will be measured at four time points: pre-intervention, at three months, six months, and at nine months. As this is the first multicenter randomized controlled trial investigating the effects of aVNT as a treatment in PWS patients, we anticipate witnessing improved emotional regulation and reduced eating disorders, along with enhancements in executive functions and quality of life in the active stimulation group. The findings from this project could support the development of broader therapeutic approaches for other conditions in which behavioral disorders and emotional processing deficits affect patients and their caregivers.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a gentle, non-invasive form of nerve stimulation — called transcutaneous vagus nerve stimulation (tVNS), delivered through the ear — can help people with Prader-Willi syndrome (PWS) better manage their emotions and improve their thinking and self-control. PWS is a rare genetic condition that causes behavioral and cognitive challenges. **You may be eligible if...** - You are 18 years or older and have been diagnosed with Prader-Willi syndrome with a confirmed genetic cause - Your IQ is 55 or above (measured by a standard test) - You score in the concerning range on a brain function self-report scale (BRIEF-A) - You have a caregiver who is involved in your care and willing to participate **You may NOT be eligible if...** - You have untreated or unstable psychiatric or behavioral problems (including a mental health crisis in the past year) - You have severe vision or hearing impairment - You have untreated sleep apnea, epileptic seizures, or a significant heart rhythm disorder - You have a pacemaker, defibrillator, or metal implant in your head - You have severe depression - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAuricular vagal neuromodulation therapy (aVNT)

The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.

DEVICESham Auricular vagal neuromodulation therapy (aVNT)

The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.


Locations(4)

Reference Center of Prader-Willi Syndrome (PRADORT)

Bordeaux, France

Reference Center of Prader-Willi Syndrome (CRMR PRADORT)

Hendaye, France

Reference Center of Prader-Willi Syndrome (PRADORT)

Paris, France

Reference Center of Prader-Willi Syndrome (PRADORT)

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06720571


Related Trials